Company: CI
Filing Date: 2025-05-02
Form Type: 10-Q
Source: 0001739940-25-000021
Chunk: 25

Company: Cigna Group
Filing Date: 2025-05-02
Form: 10-Q
Item: Part I, Item 1
Chunk 25
---
 Accounts receivable, net1,927 Other assets, including Goodwill (1)2,294 Total assets of businesses held for sale7,004 Insurance and contractholder liabilities1,579 All other liabilities831 Total liabilities of businesses held for sale$2,410 (1) Includes Goodwill of $94 million as of December 31, 2024.

Integration and Transaction-Related CostsIn 2025 and 2024, the Company incurred transaction-related costs associated with the HCSC transaction. These costs incurred consisted primarily of certain projects to separate the Company's systems, products and services; fees for legal, advisory and other professional services; and certain employment-related costs. These costs were $216 million pre-tax ($164 million after-tax) for the three months ended March 31, 2025, compared with $37 million pre-tax ($29 million after-tax) for the three months ended March 31, 2024.

Note 6 – Earnings Per Share

Basic and diluted earnings per share were computed as follows:

Three Months EndedMarch 31, 2025March 31, 2024(Shares in thousands, dollars in millions, except per share amounts)BasicEffect ofDilutionDilutedBasicEffect ofDilutionDilutedShareholders' net income (loss)$1,323 $1,323 $(277)$(277)Shares:Weighted average270,867 270,867 286,465 286,465 Common stock equivalents2,086 2,086 — — Total shares270,867 2,086 272,953 286,465 — 286,465 Earnings per share$4.88 $(0.03)$4.85 $(0.97)$— $(0.97)

For the three months ended March 31, 2025, 2.3 million outstanding employee stock options were excluded in the computation of diluted earnings per share because their effect was anti-dilutive. For the three months ended March 31, 2024, due to the Shareholders' net loss, 8.2 million outstanding employee stock options, unvested restricted stock grants and units, and strategic performance shares were excluded in the computation of diluted earnings per share because their effect was anti-dilutive.

11

The Company held approximately 134.1 million shares of common stock in treasury as of March 31, 2025,